Rejuve Biotech utilizes neural-symbolic AI and cross-organism data analysis, including insights from long-lived Methuselah flies, to expedite the development of therapeutics targeting aging and age-related diseases. By integrating genomic data from model organisms with human health information, the company aims to enhance healthspan and mitigate the impact of aging on cognitive function.
Funding
$290K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug discovery for aging and age-related diseases is slow and inefficient due to the complexity of aging biology and the limitations of traditional drug development pipelines. Analyzing the vast amount of multi-omics data required to understand aging is computationally intensive and requires advanced AI techniques.
Solution
Rejuve Biotech is developing a drug discovery platform that leverages neural-symbolic AI and cross-organism data analysis to accelerate the development of therapeutics targeting aging and age-related diseases. The platform integrates genomic data from long-lived model organisms, such as Methuselah flies, with human health information to identify key pathways and drug targets. By combining advanced AI techniques with unique animal model data, Rejuve Biotech aims to enhance healthspan and mitigate the impact of aging on cognitive function.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and longevity clinics seeking to develop and implement novel therapeutics for aging and age-related diseases.
Features
- Proprietary access to genomic and phenotypic data from Methuselah flies, a long-lived Drosophila melanogaster strain.
- Neural-symbolic AI engine that integrates neural networks, symbolic reasoning, and evolutionary algorithms for data analysis and hypothesis generation.
- Continuously updated biomedical knowledge graph integrating human and model organism databases.
- AI-driven identification of promising small molecules and compounds that act on disease targets.
- Decentralized N-of-1 trial functionality through the Rejuve Longevity App for personalized longevity optimization strategies.
- Integration of multi-omics data, including genomics, transcriptomics, and proteomics, for comprehensive analysis.